# GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer

> **NCT07489287** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Roswell Park Cancer Institute** · enrollment: 18 (estimated)

## Conditions studied

- Platinum-resistant Ovarian Cancer

## Interventions

- **BIOLOGICAL:** GB-5267 - IV only
- **BIOLOGICAL:** GB-5267 -Combined IV and IP Infusion

## Key facts

- **NCT ID:** NCT07489287
- **Lead sponsor:** Roswell Park Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-06-15
- **Primary completion:** 2028-01-15
- **Final completion:** 2030-01-15
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07489287

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07489287, "GB-5267 for the Treatment Platinum-Resistant Ovarian, Peritoneal, or Fallopian Tube Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT07489287. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*